Optimising Pacing for Contractility 2
Launched by UNIVERSITY OF LEEDS · Dec 13, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Optimising Pacing for Contractility 2" is studying how different programming settings on a pacemaker can improve exercise ability and quality of life for patients with chronic heart failure (CHF). Researchers have found that keeping the heart rate in a specific range can help patients exercise longer and feel better. This trial aims to compare three different programming methods: one that uses the optimal heart rate, one that uses standard settings, and one that doesn’t adjust the heart rate at all, over a period of six months.
To take part in this study, patients need to have chronic heart failure and a cardiac pacemaker, be able to walk on a treadmill, and be willing to give consent for the trial. Over 450 participants will undergo tests to find the best heart rate for their condition, complete a treadmill exercise test, and fill out quality of life questionnaires. Afterward, they will be randomly assigned to one of the three programming groups and will return for follow-up tests after six months. This study is important as it may lead to better management of heart failure, helping patients exercise more and improve their overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical, echocardiographic and neurohormonal evidence of heart failure
- • Cardiac pacemaker,
- • Able to perform a peak exercise test,
- • Willing and able to give informed consent.
- Exclusion Criteria:
- • Angina pectoris symptoms limiting exercise tolerance,
- • Unstable heart failure symptoms (medical therapy changes in last three months), Poor image quality,
- • Calcium channel blockers (CCBs).
About University Of Leeds
The University of Leeds is a prestigious research institution located in the United Kingdom, renowned for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, the University of Leeds leverages its diverse expertise and collaborative environment to facilitate high-quality clinical studies that aim to improve health outcomes and contribute to the scientific community. The university fosters interdisciplinary partnerships, ensuring rigorous methodologies and ethical standards in its research initiatives. By integrating cutting-edge technologies and a patient-centered approach, the University of Leeds plays a vital role in translating research findings into practical applications for healthcare improvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, , United Kingdom
Patients applied
Trial Officials
John Gierula, PhD
Principal Investigator
University of Leeds
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials